Article citationsMore>>

Cho, D.I., Ahn, J.H., Kang, B.G., Hwang, I., Cho, H.H., Jun, J.H., et al. (2025) ANGPTL4 Prevents Atherosclerosis by Preserving KLF2 to Suppress EndMT and Mitigates Endothelial Dysfunction. Arteriosclerosis, Thrombosis, and Vascular Biology, 45, 1742-1761.
https://doi.org/10.1161/atvbaha.125.322700

has been cited by the following article:

• TITLE: Schisandrin B Elevates Plasma Glutathione Redox Status and Modulates Hepatokines for Extrahepatic Metabolic Regulation

  AUTHORS: Kam Ming Ko, Hoi Yan Leung

  KEYWORDS: Schisandrin B, Plasma, Glutathione Redox Status, Hepatokines

  JOURNAL NAME: Chinese Medicine, Vol.17 No.2, June 4, 2026

  ABSTRACT: Schisandrin B (Sch B), a bioactive lignan derived from Schisandrae chinensis Fructus, exhibits well-documented tissue-protective properties, yet its systemic metabolic effects mediated by liver-derived factors remain elusive. This study investigated the capacity of Sch B to modulate systemic redox status and hepatokine secretion in a mouse model. Following oral administration of Sch B, treated animals demonstrated a significantly elevated plasma glutathione (GSH/GSSG) ratio, reflecting a robust enhancement of systemic antioxidant capacity essential for extrahepatic tissue protection. Concurrently, Sch B induced a highly favorable reprogramming of circulating hepatokines by downregulating angiopoietin-like proteins 3 and 4 (ANGPTL3 and ANGPTL4) while upregulating the insulin-sensitizing hormone adropin. Because ANGPTL3/4 act as lipase inhibitors, this coordinated shift theoretically promotes an atheroprotective lipid profile alongside enhanced energy expenditure and glucose homeostasis. Collectively, these findings demonstrate that Sch B exerts beneficial systemic metabolic effects through coupled redox enhancement and hepatokine regulation, underscoring its potential as a therapeutic agent for metabolic disorders.